Pharmaceutical and healthcare are collectively a highly important business sector for China Grand Enterprises, INC. It includes chemical pharmaceuticals, biopharmaceuticals, Chinese patent medicines, Chinese medicinal materials, Chinese herbal decoction, medical devices, medical cosmetic, pharmacies, chain drugstores, and more.
China Grand Enterprises Pharmaceuticals & Healthcare (hereinafter referred to as CGE Healthcare) owns multiple subsidiaries such as Huadong Medicine, Grand Pharmaceutical Group, Lei Yunshang Group and Grand Biotech Group. The enterprise has a worldwide marketing network, working closely with over 10,000 Level II hospitals, over 50,000 basic medical institutions and top 100 drugstores.
CGE Healthcare adheres to the business concept of "technology research-based, patients-centered and market-oriented" and has always taken innovation as the strategic focus. New products have been consistently put to market through the independent R&D platform construction, industry-teaching-research collaborative innovation and international cooperation, guaranteeing the enterprise's sustainable and rapid development. Through more than 20 years of development, the enterprise has formed a business model integrating R&D, production and sales, simultaneously developing traditional Chinese medicines, chemical medicines, biological medicines, medical devices and medical cosmetic; jointly developing domestic and international markets.
Headquartered in Hangzhou, Zhejiang, China, Huadong Medicine covers the entire pharmaceutical industry chain, with the pharmaceutical industry as its mainstay while expanding into the pharmaceutical commerce and cosmetic medicine, and is a large-scale comprehensive pharmaceutical enterprise integrating R&D, production, sales, modern logistics, health industry and medical aesthetic products manufacturing and sales. Its products cover a wide range of categories, including traditional Chinese medicine, chemical drugs, biological drugs and medical apparatus and instruments.
The core of pharmaceutical industry of Huadong Medicine is its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. The company has been deeply engaged in the R&D, production and sales of drugs for specialized diseases, chronic diseases and special drugs for decades, and has formed a core product pipeline mainly in the fields of chronic kidney disease, transplantation immunity, endocrine, digestive system, anti-tumor, etc., and has become a leading R&D and production enterprise specializing in diabetes and transplantation immunity drugs in China; many of its core products are first-line clinical drugs in China and have a dominant position in the market; the company's main APIs have been approved by the US FDA, and its products and production lines have been certified by the United States and European Union, and it has formed research and development, production, quality management systems which conform to the Sino-US and Sino-Europe dual certification standards. In the field of oncology, endocrine and autoimmune diseases, the company continues to strengthen its layout and form a product portfolio dominated by innovation, improvement and high-barrier imitation. In the field of anti-tumor, diabetes, and immune diseases, it has formed a complete product pipeline, and a number of projects are in the clinical trial stage. At the same time, the company is actively laying out innovative therapeutic tools and technologies.
In the field of pharmaceutical commerce, the company has four business segments including pharmaceutical preparations, medical apparatus and instruments, herbs and ginseng, and health industry, covering wholesale, retail, cold chain distribution, e-commerce, hospital value-added services and special health industry, to provide customers with comprehensive solutions. The company is the designated service provider of cold chain distribution in Zhejiang Province. In 2020, the company organized and completed the distribution of the first batch of COVID-19 vaccine to many provincial hospitals in accordance with the distribution instruction of Zhejiang Provincial Center for Disease Control and Prevention for immunization planning. In 2021, it obtained the first Cold Chain Enterprise Express Business Operation License in Zhejiang Province, and was exclusively qualified for the third-party storage and transportation of vaccines by Zhejiang Provincial Center for Disease Control and Prevention.
The company's cosmetic medicine business adopts the strategy of " Global Operation Layout and Dual Cycle Business Development", focusing on the R&D, production and sales of non-surgical mainstream cosmetic medicine products such as facial fillers, body firming, thread embedding and energy source devices, and has formed a comprehensive product cluster of differentiated sodium hyaluronate total product portfolio, collagen stimulator, botulinum toxin type A, thread embedding and energy source devices. At present, it has four R&D centers including wholly-owned subsidiaries Sinclair in the UK, High Tech in Spain, joint stock companies R2 in the US and Kylane in Switzerland, as well as five production bases in Holland, France, the United States, Switzerland and Bulgaria, with its core products launching in more than 60 countries and regions worldwide. The company has formed product echelon in the field of medical cosmetology. In April 2021, Sinclair's core product, Ellansé, a new collagen stimulator, received NMPA marketing approval and is expected to be officially launched in mainland China in the second half of 2021. Meanwhile, a number of cosmetic medicine products are undergoing clinical research and registration review.
In recent years, the company has continued to increase its investment in technological innovation,” Acarbose Raw Material and Preparation Industrialization Key Technology", "Pantoprazole Sodium and Preparation Key Technology Research and Industrialization", "Key Technology and its Application of New Process in the Manufacture of cyclosporine A" were awarded the second prize of National Science and Technology Progress. With outstanding performance and good governance, the company has been honored and awarded for many times by Forbes as one of the "Top 50 Best Listed Companies in Asia Pacific", " Top 100 Listed Companies on the Main Board Companies in China", and has been listed on the Fortune 500 China for many years.
Grand Pharmaceutical, with Grandpharma (China) Co., Ltd, as the main body, is a global comprehensive enterprise engaged in research, development, production and sales of pharmaceutical products. Our core products are involved in cardiovascular emergency, high-end medical devices, antiviral and anti-infection, respiratory and ophthalmology and otorhinolaryngology, anti-tumor, bio-health products, and fine APIs. The Company has established arrays of sound manufacturing bases in China, United States, Canada, Germany and Singapore with comprehensive sales network covering more than 60 countries and regions globally.
Currently, CGP owns four robust R&D platforms geographically located in different countries including that in radionuclide-drug conjugate (RDC) technology, DNA R&D, mRNA R&D, and glycomics R&D; as well as five R&D centers which include San Diego R&D Center (immunotherapy DNA technology anti-tumor), Boston R&D Center (precision interventional anti-tumor), Belgium (respiratory, ophthalmology and mRNA), Australia R&D Center (antiviral and anti-infection), and Optics Valley R&D Center in Wuhan. CGP also has over 30 internationally renowned scientists with high profiles and a R&D team of over 500 staff with more than half of them as masters and PhD degree holders.
CGP is committed to building a leading international platform for cardiovascular and cerebrovascular precision interventional diagnosis and treatment. Currently, two products, RESTORE DEB and APERTO OTW, have been approved by NMPA for marketing in China. RESTORE DEB is the only innovative coronary interventional balloon with dual indications of primary coronary vascular lesions and in-stent restenosis of its kind; APERTO OTW is the first kidney dialysis drug-coated balloon for dialysis patients.
In the field of Oncology, a global layout has been focusing on radionuclide and tumor immunology. So far, CGP has licensed in over 12 overseas innovative products covering numbers of major solid tumors, which contributes to company into a place as industry-leading status in products number, pipeline and variety. Among them, SIR-Spheres® yttrium [90Y] resin microspheres have been submitted to the National Medical Products Administration for the NDA approval to be marketed in China, which will bring a novel therapeutic option to treat metastatic liver cancer. Furthermore, the core product of IL-12 coding TAVOTM from OncoSec Medical, CGP own subsidiary company, in combination with checkpoint inhibitor KEYTRUDA (Pembrolizumab) in the treatment of anti-PD-1 checkpoint resistant metastatic melanoma, has demonstrated excellent anti-tumor effects in currently ongoing clinical trials in USA.
In the field of antiviral and anti-infection, we focus on globally pioneered drugs with significant unmet clinical needs. Two innovative programs have been developed for the treatment of sepsis and one for the treatment of parainfluenza. The APAD program for sepsis has been approved for Phase Ib clinical study in China, and the program has also been approved for Phase II clinical study for COVID-19-induced ARDS and Phase Ib clinical study for sepsis in Australia.
For mRNA research, we have established a strategic cooperation and joint venture with eTheRNA Immunotherapies NV in Belgium, equipping our capability to compete with the mRNA global leaders.
Under CGP comprehensive pipelines, the traditional but advantageous fields including respiratory, ophthalmology and otorhinolaryngology. Three innovative products, currently in clinic stage, are also provided for the treatment of dry eye, pterygium and allergic rhinitis.
In the future, CGP will continue to focus on patients’ needs, adapt to market changes and adhere to the principle of innovation-driven. Guided by the development concept of “comprehensive advantages, innovation barriers and global expansion”, great efforts will be continually made to strive for the formation of a new pattern of joint development and mutual reinforcement in home and aboard by adopting the strategy of combining self-independent innovation and global expansion and seeking development with global operation and double-cycle business model. All the efforts show company dedication to become a scientific and innovative international pharmaceutical enterprise respected by doctors and patients, and ultimately serving the society.
Lei Yunshang, founded in 1734, is one of the four major Chinese pharmacies, the owner of the first batch of Chinese time-honored brands, national top secret projects and national intangible cultural heritage. Taking "Lei Yunshang" (with a history of nearly 300 years) as the unified brand, and "gathering various herbs and benefiting the people" as the mission, Lei Yunshang Pharmaceutical Group adheres to the brand idea of "300-year Lei Yunshang passes down health wisdom" and strictly follows the ancestral teachings of "selecting genuine medicinal materials to produce high-quality medicines," while inheriting and carrying forward the essence of the doctrine of seasonal febrile diseases. Based on traditional Chinese medicine and fully absorbing modern scientific and technological achievements, the group is actively transforming itself into an innovative Chinese medicine manufacturing enterprise driven by both technology and brand, and has become a large-scale traditional Chinese medicine group with unique advantages in many disease treatment fields.
The product line of Lei Yunshang Pharmaceutical Group covers 8 clinical treatment fields, such as medicines for the respiratory system, medicines for the urinary system, tonics, medicines for the digestive system, gynecology, pediatrics and brain medicines, medicines for cardiovascular and cerebrovascular diseases, and antineoplastic drugs. The main medicine covers many approved products by the National Medical Products Administration (NMPA), such as tablets, powders, granules, pills, capsules and ointments. The group has many products, national secret formulas and national protected varieties of traditional Chinese medicine. Moreover, the group has multiple products by application of two national top-secret formulas listed in the national intangible cultural heritage catalog, such as Liushen Pill, "national drug approval No.1" Jianyanling Capsule and Kuhuang series products, Capsule for Nourishing Lung & Activating Blood Circulation, Xiaozheng Pill, Compound Cistanche Nootropic Capsule, Naoan Drop Pill, Lingbao Heart Protection Pill, and other important products. The group has formed a dimensional product pattern based on the respiratory and cardio-cerebrovascular market, covering the traditional advantages of Chinese patent medicine, focusing on major diseases and cultivating large varieties.
Lei Yunshang Group always adheres to the principle of patient-centered, adhering to the integrity and innovation of traditional Chinese medicine, and comprehensively carries out the secondary development and innovation research of traditional Chinese medicine from the aspects of safety, pharmacy, pharmacology and clinical to construct the evidence-based evidence chain of products and enhance the scientific connotation and market competitiveness of products. With academicians and front-line experts as the members of research and development consulting team, Lei Yunshang Group has built four R&D innovation platforms including Chinese medicine mini-pill preparation research and development technology platform, Chinese medicine quality analysis technology platform, respiratory drug efficacy evaluation technology platform and liposome research and development platform. In the field of respiration, we cooperate with Zhong Nanshan academician team of the State Key Laboratory of Respiratory Diseases (Guangzhou Medical University) and elucidate the anti-inflammatory and antiviral mechanism of Liushen products by modern biomedical technology, and Liushen Pill ranked second in the list of scientific and technological competitiveness of big varieties of traditional Chinese medicine, and won the title of heritage classic Chinese patent medicine brand. In the urological field, after more than 20 years of clinical application, it has been proved that Shenshuaining Capsule in clinical application can interfere with the progression of nephropathy with multiple targets, improve the clinical symptoms of patients with chronic renal failure, increase eGFR, effectively reduce creatinine and urea nitrogen, stabilize residual renal function, and delay the progression of nephropathy. In the field of tonifying, Jianyanling Capsule evolved from the experience prescription of "Buyi Shenqi Jingxue Formula" by Mr. Shi Jinmo, one of the four famous doctors in Beijing, has become the first national health medicine with anti-fatigue, anti-aging and prolongation of life, which is worthy of the name of "No. 1" health care drug. In the field of digestion, through the international advanced artificial liver technology based on tissue engineering, the group clarifies the exact role and key mechanism of Kuhuang series products in endoplasmic reticulum emergency, oxidative damage, hepatic fibrosis, normalizing gallbladder to cure jaundice, reliving steatosis, immune regulation and reconstruction, liver regeneration and apoptosis. In the field of gynecology and pediatrics with Chinese medical characteristics, combining the methods of network pharmacology, serum metabolomics and molecular biology technology, we will comprehensively explore and clarify the possible mechanism of action and potential therapeutic targets of the Xiaozheng Pill in inhibiting hyperplasia of mammary glands, and has won the second prize of Suzhou Science and Technology Progress Award and the second prize of Jiangsu Traditional Chinese Medicine Science and Technology Award. In the field of brain with Chinese medical characteristics, through modern clinical studies, it can be found that Compound Cistanche Nootropic Capsule can increase the degree of brain regions activated, prevent the hippocampus atrophy, inhibit T - tau protein aggregation, improve cerebral blood flow and vascular endothelial function, to fill the gaps of Chinese patent medicine in the field the treatment of dementia in China, has won the first prize in China university of science and technology, national scientific and technological progress second prize and a series of honors. As a result of the national "Eighth Five-Year Plan" research project, Naoan drop pills have clear pharmacological effects, which can effectively inhibit thrombosis, inhibit platelet aggregation, increase blood supply to the brain, protect ischemic brain tissue, and reduce oxidative stress. In the cardiovascular field with Chinese medical characteristics, we explore the protective mechanism of Lingbao Heart Protection Pill on the occurrence and development of atherosclerosis, and myocardial ischemia, as well as the exact role and key mechanism in inhibiting and improving bradycardia by multi-channel and multi-target treatment. In the field of anti-tumor, the first Chinese medicine anti-tumor emulsions listed in China: brucea oil emulsion injection and brucea oil oral solution, are widely used in the clinical treatment of lung cancer, lung cancer brain metastasis and digestive tract tumors.
Lei Yunshang Pharmaceutical Group is committed to combining traditional Chinese medicine prescriptions with modern pharmacology. This is accomplished through adjusting Chinese traditional medicine for precise treatment, through scientific interpretation of the mechanism of action, precise mining of clinical value, and truly realizing the innovation and inheritance of traditional Chinese medicine, providing more precise traditional Chinese medicine treatment methods and combined solutions for patients.
Grand Life Sciences Group Limited (hereinafter referred to as "Grand Life Sciences") is a modern comprehensive pharmaceutical enterprise focusing on biomedicine and integrating research, development, production and sales of pharmaceutical products. The company has set up a global team, with excellent R & D personnel, diversified product pipeline, stable business partners and rich marketing experience.
With a global perspective, Grand Life Sciences studies the future industry reform trend, aims at the international and domestic clinical needs that have not been met, focuses on the frontier of innovation targets, and carries out the development of innovative drugs such as new antibodies, high-end blood products, new recombinant vaccines, new generation of live bacteria agents and gene recombinant polypeptides. The company has established technology platforms for blood product R&D and production, recombinant protein technology, innovative adjuvant vaccine development, functional microorganism live bacteria screening, complex drug delivery, biodegradable implant materials, etc., effectively completing the transformation from a traditional biopharmaceutical enterprise to an international modern biotechnology pharmaceutical enterprise group.
Grand Life Sciences has been deeply engaged in bio-extracts, blood products, vaccines and micro-ecological formulations. It has subsidiaries and production bases in Chengdu, Hangzhou, Shenyang, Chongqing, Nanjing, Zhengzhou, Penglai and other places, and its products covers digestion and metabolism, blood products, perioperative and wound management, infectious disease prevention and treatment and other fields.
In the field of digestion and metabolism, the leading product of Hangzhou Grand Biologic Pharmaceutical INC., "Bifidobacterium Tetravaccine Tablets (Siliankang)", is a multi-linked micro-ecological bacteriological product with independent invention patent and has been listed into the national medical insurance drug catalog. "Clostridum Butyricum Capsule (Misang)" is the third generation of live bacteria preparation, containing the self-developed RH-2 strain of human native bacteria. The company has built a functional microbial library with independent intellectual property rights. With the continuous improvement of the library capacity, more live bacteria drugs can be provided to patients in the future, and the microbial products will also be used as a new drug delivery platform to play the advantage of in situ colonization release to play a role in more therapeutic areas.
In the field of blood products, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (hereinafter referred to as SHUYANG), one of the first batch of China's designated blood products production enterprises, has human serum albumin, human immunoglobulin for intravenous injection and other products with 8 series of 23 specifications, which have been exported to more than 10 countries after meeting the domestic sales demand. The company has invested more than 3 billion yuan to build a new plant that is in line with Chinese GMP standards and meets the EU and WHO standards whose monomer production capacity is the first in Asia and top 10 in the world. In the future, SHUYANG will build a blood product platform with the world's first research and development planning variety structure and a biomedicine platform with international cutting-edge monoclonal antibodies, so as to build an innovative international biomedicine enterprise with dual-track development.
Liaoning Grand Nuokang Biopharmaceutical Co., Ltd. focuses on perioperative management and wound management products. The company has a professional R&D center concentrating on innovative drugs and medicines, and high-technical-barrier emulsion R&D center, enzyme engineering as well as medical device R&D and production transformation platform, with corresponding comprehensive modern production bases of various preparations, active pharmaceutical ingredients (API) base and Peru snake venom supply base. The company is committed to providing original biopharmaceuticals, complicated high-end preparations and medical devices with biodegradable materials. The core products include Baquting®, Kaitong®, Fu Dingle®, Aido®, ROPION®, collagenase, PPDO suture, etc. Hemocoagulase Atrox for Injection (Baquting®) has obtained the Chinese invention patent (pharmaceutical composition patent), and the national drug standards of the product has been formulated. It is the only snake venom hemostatic drug recorded in the Chinese Pharmacopoeia, setting a new milestone for China's hemostatic drugs. Flurbiprofen Axetil Injection (ROPION®) is mainly used for postoperative and cancer analgesia. It is the first special injection that has passed the consistency evaluation in China and the first injection selected in the Catalog of Chinese Marketed Drugs. Collagenase for Injection is a national Class 1 new drug, the only enzyme drug recommended by expert consensus for the treatment of lumbar disc herniation. Collagenase Ointment is the "national Class 3.1" drug, the only enzyme drug for debridement officially approved by FDA, and the exclusive national product. At present, the company has 77 patents and 17 varieties under development, including 2 Class 1 new drugs, 1 Class 2 new drugs, 2 Class 3 new drugs, 11 Class 4 new drugs and 1 Other new drug.
In the field of infectious disease prevention and control, the human rabies vaccine of Henan Grand Biologic Pharmaceutical Co., Ltd. has pioneered the adjuvant-free rabies vaccine in China and has been marketed and sold for more than ten years. Based on Nanjing Grand Theravac Biopharmaceutical Co., Ltd., Grand Life Sciences Bio-vaccine R&D Center has been established, focusing on the research and development of new vaccines and therapeutic vaccines. At present, the company has the core technology platform for vaccine development centered on an Escherichia coli (E. coli) and yeast recombinant vaccine platform with independent intellectual property rights, a large-scale fermentation platform, a protein vaccine purification process platform, a recombinant VLP-based vaccine quality evaluation platform, and an immune evaluation platform. Meantime, the company has a pilot plant for recombinant protein vaccine, and A2 and P2 biosafety laboratories, all of which cover a total area of about 10000sq.km, and can meet the needs of R&D, pilot production, clinical sample preparation for Phase I and Phase II clinical trials, etc. The company has more than 10 research and development pipeline projects, all of which are Class 1 innovative drugs, among which therapeutic hepatitis B vaccine TVAX-008 injection, a Class 1 innovative drug officially entered the Phase I clinical research in 2021.
In the future, Grand Life Sciences will continue to strengthen the company's development advantages, adhere to innovation as the driving force, continue to build core competitiveness, strengthen the high-end talent pool, build a great talent pool for the company's development, and strive to develop into a first-class enterprise with global competitive advantages.
With the acceleration of China's medical system reform, guided by the enterprise spirit of "loyalty, simplicity, diligence and innovation", CGE Healthcare will adhere to the principle of quality first and development through innovation, always take "serving the society" as the highest mission, expand future business through innovative cooperation, and continuously make contributions to the society.
Huadong Medicine Ellansé’s Official Launch in China Met with Wide Acclaim by Authorities in the Medical Beauty Industry
Hubei and Henan Stand Together Regardless of Situation - Grandpharma donated 1 million yuan worth of stock medicines for Henan flood relief
Grandpharma Signed a Strategic Cooperation Agreement with Wuhan Jinyintan Hospital
Chengdu Grand Bay Hotel Was Officially Opened
HomePark, Grand Shopping Center was Ranked in"The Best Stores of China 2020"
Huadong Medicine obtained the Ellansé® (Apolycaprolactone Microsphere Facial Filler for Injection Use) Medical Device Registration Certificate